RESEARCH FELLOWSHIP TO STUDY HIV VACCINES
Grant number: 1041832 | Funding period: 2013 - 2017
I am an infectious diseases physician and virologist/immunologist focused on developing and testing vaccines against the AIDS virus. I intend to achieve this by advancing novel vaccine concepts that stimulate broad and potent immunity and evaluating these vaccines in rigorous laboratory models and then moving them towards clinical trials.
Related publications (13)
Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?
Deborah Cromer, Mykola Pinkevych, Thomas A Rasmussen, Sharon R Lewin, Stephen J Kent, Miles P Davenport
A number of treatment strategies are currently being developed to promote antiretroviral therapy-free HIV cure or remission. While..
Fc functional antibodies in humans with severe H7N9 and seasonal influenza
Hillary A Vanderven, Lu Liu, Fernanda Ana-Sosa-Batiz, Thi HO Nguyen, Yanmin Wan, Bruce Wines, P Mark Hogarth, Danielle Tilmanis, Arnold Reynaldi, Matthew S Parsons, Aeron C Hurt, Miles P Davenport, Tom Kotsimbos, Allen C Cheng, Katherine Kedzierska, Xiaoyan Zhang, Jianqing Xu, Stephen J Kent
BACKGROUND: Both seasonal and novel avian influenza viruses can result in severe infections requiring hospitalization. Anti-influe..
Charge Has a Marked Influence on Hyperbranched Polymer Nanoparticle Association in Whole Human Blood
Joshua J Glass, Liyu Chen, Sheilajen Alcantara, Edmund J Crampin, Kristofer J Thurecht, Robert De Rose, Stephen J Kent
In this study, we synthesize charge-varied hyperbranched polymers (HBPs) and demonstrate surface charge as a key parameter directi..
Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days
Mykola Pinkevych, Stephen J Kent, Martin Tolstrup, Sharon R Lewin, David A Cooper, Ole S Sogaard, Thomas A Rasmussen, Anthony D Kelleher, Deborah Cromer, Miles P Davenport
Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine
Anne B Kristensen, William N Lay, Fernanda Ana-Sosa-Batiz, Hillary A Vanderven, Vijaya Madhavi, Karen L Laurie, Louise Carolan, Bruce D Wines, Mark Hogarth, Adam K Wheatley, Stephen J Kent
UNLABELLED: This study seeks to assess the ability of seasonal trivalent inactivated influenza vaccine (TIV) to induce nonneutrali..
High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo
Sarah B Lloyd, Marit Lichtfuss, Thakshila H Amarasena, Sheilajen Alcantara, Robert De Rose, Gilda Tachedjian, Hamid Alinejad-Rokny, Vanessa Venturi, Miles P Davenport, Wendy R Winnall, Stephen J Kent
The low fidelity of HIV replication facilitates immune and drug escape. Some reverse transcriptase (RT) inhibitor drug-resistance ..
HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission
Mykola Pinkevych, Deborah Cromer, Martin Tolstrup, Andrew J Grimm, David A Cooper, Sharon R Lewin, Ole S Sogaard, Thomas A Rasmussen, Stephen J Kent, Anthony D Kelleher, Miles P Davenport
HIV infection can be effectively controlled by anti-retroviral therapy (ART) in most patients. However therapy must be continued f..
Simian immunodeficiency virus infection and immune responses in the pig-tailed macaque testis
Wendy R Winnall, Sarah B Lloyd, Robert De Rose, Sheilajen Alcantara, Thakshila H Amarasena, Mark P Hedger, Jane E Girling, Stephen J Kent
The testis is a site of immune privilege in rodents, and there is evidence that T cell responses are also suppressed in the primat..
The maturation of antibody technology for the HIV epidemic
Wendy R Winnall, Matthew D Beasley, Rob J Center, Matthew S Parsons, Ben R Kiefel, Stephen J Kent
Antibodies are one of our most useful biological tools. Indeed, improvements in antibody-based technologies have ushered in a new ..
Characterisation of macaque testicular leucocyte populations and T-lymphocyte immunity
Robert De Rose, Caroline S Fernandez, Mark P Hedger, Stephen J Kent, Wendy R Winnall
The rodent testis is well established as a site of immune privilege where both innate and acquired immune responses are suppressed..